Cargando…
Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens
In the context of a Phase I clinical trial, the long-term vaccination of advanced biliary tract cancer patients with peptides derived from four distinct cancer-testis antigens resulted in remarkable disease stability and in the elicitation of antigen-specific T-cell responses.
Autor principal: | Aruga, Atsushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782136/ https://www.ncbi.nlm.nih.gov/pubmed/24073370 http://dx.doi.org/10.4161/onci.24882 |
Ejemplares similares
-
Cancer testis antigens: A new paradigm for cancer therapy
por: Suri, Anil, et al.
Publicado: (2012) -
Detection of cancer/testis antigens as a diagnostic tool in routine pathology practice
por: Chen, Yao-Tseng
Publicado: (2014) -
TEIPP peptides: exploration of unTAPped cancer antigens
por: Marijt, Koen A., et al.
Publicado: (2019) -
Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015) -
Cell-penetrating peptides—the Swiss Army knife of cancer vaccines
por: Walker, Paul R., et al.
Publicado: (2015)